Ciências Químicas e das Biomoléculas, Escola Superior de Tecnologia da Saúde do Porto do Instituto Politécnico do Porto, Rua Valente Perfeito 322, 4400-330 Vila Nova de Gaia, Portugal.
ChemMedChem. 2011 Jun 6;6(6):975-85. doi: 10.1002/cmdc.201100082. Epub 2011 May 9.
Ionic liquids (ILs) are ionic compounds that possess a melting temperature below 100 °C. Their physical and chemical properties are attractive for various applications. Several organic materials that are now classified as ionic liquids were described as far back as the mid-19th century. The search for new and different ILs has led to the progressive development and application of three generations of ILs: 1) The focus of the first generation was mainly on their unique intrinsic physical and chemical properties, such as density, viscosity, conductivity, solubility, and high thermal and chemical stability. 2) The second generation of ILs offered the potential to tune some of these physical and chemical properties, allowing the formation of "task-specific ionic liquids" which can have application as lubricants, energetic materials (in the case of selective separation and extraction processes), and as more environmentally friendly (greener) reaction solvents, among others. 3) The third and most recent generation of ILs involve active pharmaceutical ingredients (API), which are being used to produce ILs with biological activity. Herein we summarize recent developments in the area of third-generation ionic liquids that are being used as APIs, with a particular focus on efforts to overcome current hurdles encountered by APIs. We also offer some innovative solutions in new medical treatment and delivery options.
离子液体 (ILs) 是指在 100°C 以下具有熔融温度的离子化合物。它们的物理和化学性质具有吸引力,适用于各种应用。目前被归类为离子液体的几种有机材料早在 19 世纪中期就已经被描述过。对新型和不同离子液体的探索导致了三代离子液体的逐步发展和应用:1) 第一代的重点主要在于其独特的内在物理和化学性质,如密度、粘度、电导率、溶解度以及高热和化学稳定性。2) 第二代离子液体提供了调整其中一些物理和化学性质的潜力,允许形成“特定用途的离子液体”,这些液体可用作润滑剂、高能材料(在选择性分离和提取过程的情况下)以及更环保(更绿色)的反应溶剂等。3) 第三代也是最新一代的离子液体涉及活性药物成分 (API),正在被用于生产具有生物活性的离子液体。本文总结了第三代离子液体作为 API 的最新进展,特别关注克服 API 当前遇到的障碍的努力。我们还提供了一些在新的医疗治疗和给药选择方面的创新解决方案。
ChemMedChem. 2011-5-9
ChemMedChem. 2017-1-5
Int J Pharm. 2012-10-30
Curr Drug Res Rev. 2020
Bioorg Med Chem Lett. 2009-8-15
J Chromatogr A. 2009-9-10
Int J Pharm. 2013-8-23
Chemphyschem. 2025-7-2
Food Chem X. 2025-2-3
Adv Sci (Weinh). 2024-11